Tissue-Specific MR Imaging in Multiple Sclerosis

References

1. ↵
   Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapse in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:270–77
2. ↵
   Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006;59:597–05

   CrossRefPubMedWeb of Science
3. ↵
   Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–45

   CrossRefPubMedWeb of Science
4. ↵
   Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073–81

   CrossRefPubMedWeb of Science
5. ↵
   Arnold DL. Evidence for neuroprotection and remyelination using imaging techniques. Neurology 2007;68 (suppl 3):S83–S90

   Abstract/FREE Full Text
6. ↵
   Van Walderveen MA, Barkhoff F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684–90

   Abstract/FREE Full Text
7. ↵
   Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003;126 (Pt 8):1782–89

   Abstract/FREE Full Text
8. ↵
   Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007;68 (suppl 3):S72–S82

   Abstract/FREE Full Text
9. ↵
   Filippi M, Rovaris M, Rocca MA, et al, and the European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes.” Neurology 2001;57:731–33

   Abstract/FREE Full Text
10. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407–13

    CrossRefPubMedWeb of Science
11. ↵
    Bagnato F, Gupta S, Richert ND, et al. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol 2005;62:1684–88

    CrossRefPubMedWeb of Science
12. ↵
    Van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlates of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–88

    Abstract/FREE Full Text
13. ↵
    Li BS, Moriarty DM, Regal J, et al. In vivo 3D 1H MRS of T1-hypointense lesions in relapsing-remitting multiple sclerosis. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Glasgow, Scotland, UK, April 21–27,2001
14. ↵
    Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739–52

    PubMedWeb of Science
15. ↵
    Fritz D, Dwyer MG, Quadros C, et al. T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis. J Neurol 2006;253:104–26
16. ↵
    Riva M, Ikonomidou VN, Ostuni JJ, et al. Tissue-specific imaging as a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage. AJNR Am J Neuroradiol 2009;30:1394–401

    Abstract/FREE Full Text
17. ↵
    Miller DH. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284–94

    Abstract/FREE Full Text
18. ↵
    Rice C, Scolding N. Strategies for achieving and monitoring myelin repair. J Neurol 2007;254:275–83

    CrossRefPubMedWeb of Science